>

Zealand Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>ZEA</div>
ZEAL -- Denmark Stock  

DKK 212.40  12.40  5.52%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Zealand Pharma AS is 'Sell'. Macroaxis provides Zealand Pharma buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZEAL positions. The advice algorithm takes into account all of Zealand Pharma AS available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ZEAL buy-and-hold perspective. Check out Zealand Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.
View Advice For
Refresh

Time Horizon

Risk Tolerance

Execute Advice
Sell Zealand PharmaBuy Zealand Pharma
Sell

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Zealand Pharma AS has a mean deviation of 3.74, semi deviation of 6.23, standard deviation of 5.49, variance of 30.15, downside variance of 48.79 and semi variance of 38.84
Macroaxis provides buy or sell recommendation on Zealand Pharma to complement and cross-verify current analyst consensus on Zealand Pharma AS. Our buy or sell advice engine determines the company potential to grow exclusively from the perspective of investors current risk tolerance and investing horizon. To make sure Zealand Pharma AS is not overpriced, please check out all Zealand Pharma AS fundamentals, including its Current Valuation, Price to Earning, Price to Sales, as well as the relationship between Shares Outstanding and Price to Book .

Zealand Pharma Trading Alerts and Improvement Suggestions

Zealand Pharma AS has very high historical volatility over the last 30 days
The company reported revenue of 42.96 M. Net Loss for the year was (508.24 M) with profit before overhead, payroll, taxes, and interest of 40.92 M.
ZEALAND PHARMA has accumulated about 1.54 B in cash with (390.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 43.11.
Latest headline from www.globenewswire.com: Zealand Pharmas Annual General Meeting 2020 Copenhagen Stock ExchangeZEAL - GlobeNewswire

Zealand Pharma current analysts recommendations

Target Median Price151.42
Target Mean Price151.13
Target High Price190.72
Number Of Analyst Opinions10
Target Low Price92.00

Zealand Pharma Returns Distribution Density

Mean Return0.19Value At Risk12.84
Potential Upside6.98Standard Deviation5.49
 Return Density 
    
  Distribution 

Zealand Pharma Greeks

α
Alpha over DOW
=0.22
β
Beta against DOW=0.16
σ
Overall volatility
=5.57
Ir
Information ratio =0.08

Zealand Pharma Volatility Alert

Zealand Pharma AS exhibits above average semi-deviation of 6.23 for selected time horizon. We encourage investors to investigate Zealand Pharma AS individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Zealand Pharma future systematic risk.
    
 Better Than Average     
    
 Worse Than Average Compare Zealand Pharma to competition

Zealand Pharma Fundamental Vs Peers

FundamentalsZealand PharmaPeer Average
Return On Equity0.0069 (0.31) 
Return On Asset0.57 (0.14) 
Profit Margin(77.37) (1.27) 
Operating Margin(58.14) (5.51) 
Current Valuation6.38 B16.62 B
Shares Outstanding35.99 M571.82 M
Price to Earning12.66 28.72 
Price to Book6.49 9.51 
Price to Sales199.74 11.42 
Revenue42.96 M9.43 B
Gross Profit40.92 M27.38 B
EBITDA(1.64 B)3.9 B
Net Income(508.24 M)570.98 M
Cash and Equivalents1.54 B2.7 B
Cash per Share43.11 5.01 
Total Debt85.76 M5.32 B
Debt to Equity4.80 48.70 
Current Ratio5.18 2.16 
Book Value Per Share34.53 1.93 K
Cash Flow from Operations(390.18 M)971.22 M
Earnings Per Share(15.71) 3.12 
Price to Earnings To Growth(0.41) 4.89 
Number of Employees17918.84 K
Beta1.07-0.15
Market Capitalization8.26 B19.03 B
Total Asset535 M29.47 B
Retained Earnings154 M9.33 B
Working Capital463 M1.48 B
Current Asset517 M9.34 B
Current Liabilities54 M7.9 B
Z Score54.38.72

Zealand Pharma Market Momentum

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page